Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings…
© 2023 The Abundance Pub. All rights reserved.
All trademarks and service marks are the property of their respective owners. This site is not intended to provide, and does not constitute, medical, health, legal, investment, financial or other professional advice.